DECR1: A Potential Drug Target and Biomarker (G1666)

Target Name: DECR1

NCBI ID: G1666

DECR1

DECR1: A Potential Drug Target and Biomarker

DECR1, short for decanoy-conjugated estrogen receptor 1, is a protein that is expressed in various tissues and cells in the body. It plays a crucial role in the regulation of cellular processes, including cell growth, apoptosis, and hormone signaling. DECR1 has also been identified as a potential drug target and biomarker for various diseases, making it an attractive molecule for research and development of new treatments.

The decanoy-conjugated estrogen receptor 1 (DECR1) is a transmembrane protein that is expressed in various tissues and cells in the body. It is a key regulator of hormone signaling, particularly in the context of estrogen. DECR1 functions as a receptor for estrogen, allowing it to transmit signals from the hormone in the body to the cell. It is composed of four transmembrane domains: an extracellular domain, a transmembrane domain, an intracellular domain, and an N-terminal domain.

One of the most significant functions of DECR1 is its role in cell growth and apoptosis. DECR1 has been shown to play a negative role in the regulation of cell growth by suppressing the S/TIM-3 signaling pathway. This pathway is involved in the regulation of cell size, survival, and angiogenesis, and is a key factor in the development of cancer. By suppressing this pathway, DECR1 has been shown to promote cell death, apoptosis, and regression in various types of cancer.

DECR1 has also been shown to play a role in the regulation of cell apoptosis. DECR1 has been shown to interact with the protein Bcl-2, which is a transcription factor that is involved in the regulation of apoptosis. By interacting with Bcl-2, DECR1 has been shown to promote the expression of genes that are involved in the regulation of apoptosis, including Bcl-2 itself. This suggests that DECR1 may play a role in the regulation of cell apoptosis, which could be a potential drug target for cancer treatments.

In addition to its role in cell growth and apoptosis, DECR1 has also been shown to play a role in the regulation of hormone signaling. DECR1 is a receptor for estrogen, which is a hormone that plays a crucial role in the regulation of various physiological processes in the body, including female reproductive function, bone density, and cardiovascular health.

DECR1 has been shown to play a negative role in the regulation of estrogen signaling by inhibiting the function of the estrogen receptor alpha (ER伪). ER伪 is a protein that is involved in the regulation of estrogen signaling, and is a key target for many anti-estrogenic drugs. By inhibiting the function of ER伪, DECR1 has been shown to reduce the activity of ER伪, which could be a potential drug target for anti-estrogenic drugs.

DECR1 has also been shown to play a role in the regulation of cell signaling pathways that are involved in the development of cancer. For example, DECR1 has been shown to play a negative role in the regulation of the TGF-β pathway, which is involved in the regulation of cell growth, angiogenesis, and the development of cancer.

DECR1 has also been shown to play a role in the regulation of inflammation. DECR1 has been shown to interact with the protein NF-kappa-B, which is involved in the regulation of inflammation. By interacting with NF-kappa-B, DECR1 has been shown to promote the expression of genes that are involved in inflammation, which could be a potential drug target for anti-inflammatory treatments.

In conclusion, DECR1 is a protein that has been shown to play a crucial role in the regulation of various physiological processes in the body. Its functions as a potential drug target and biomarker make it an attractive molecule for research and development of new treatments. Further research is needed to fully understand the role of DECR1 in

Protein Name: 2,4-dienoyl-CoA Reductase 1

Functions: Auxiliary enzyme of beta-oxidation. It participates in the metabolism of unsaturated fatty enoyl-CoA esters having double bonds in both even- and odd-numbered positions in mitochondria. Catalyzes the NADP-dependent reduction of 2,4-dienoyl-CoA to yield trans-3-enoyl-CoA

The "DECR1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DECR1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets